Holen Sie sich die Stockscreener-App
168.91
0.92%
1.54
Vorhandelsmarkt:
168.89
-0.02
-0.01%
Schlusskurs vom Vortag:
$167.37
Offen:
$166.73
24-Stunden-Volumen:
539.56K
Relative Volume:
0.60
Marktkapitalisierung:
$8.32B
Einnahmen:
$4.02B
Nettoeinkommen (Verlust:
$-79.62M
KGV:
-108.62
EPS:
-1.5551
Netto-Cashflow:
$543.67M
1W Leistung:
-5.94%
1M Leistung:
+1.77%
6M Leistung:
+5.74%
1J Leistung:
+1.37%
1-Tages-Spanne:
$166.47
$170.16
1-Wochen-Bereich:
$166.47
$182.65
52-Wochen-Spanne:
$91.86
$228.88
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
168.91 | 8.32B | 4.02B | -79.62M | 543.67M | -1.5551 |
|
TMO
Thermo Fisher Scientific Inc
|
495.72 | 184.15B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
195.06 | 137.93B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
600.52 | 47.82B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
115.42 | 32.62B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
297.54 | 29.19B | 3.17B | 642.63M | 516.49M | 10.77 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-11-17 | Hochstufung | Argus | Hold → Buy |
| 2025-11-06 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-09-09 | Hochstufung | Jefferies | Hold → Buy |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-05-23 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-05-08 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-03 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
| 2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
| 2024-10-23 | Eingeleitet | CLSA | Underperform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
| 2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Herabstufung | Argus | Buy → Hold |
| 2024-06-07 | Eingeleitet | Mizuho | Neutral |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Natixis Advisors LLC Acquires 20,050 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Barclays PLC Reduces Holdings in Charles River Laboratories International, Inc. $CRL - MarketBeat
Locus Cell, Taiwan-Based Cell and Gene Therapy CDMO, Signs MoU with Charles River at APAC Biomanufacturing Leadership Summit - PR Newswire
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
[Latest] Global Pharmaceutical Microbiology QC Testing Market Size/Share Worth USD 17.65 Billion by 2035 at a 13.27% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, SWOT Analysis) - GlobeNewswire Inc.
CRL: Biotech demand is recovering, tech investments continue, and acquisitions strengthen core focus - TradingView
CRL: Biotech demand rebounds, portfolio streamlined, and China’s innovation eyed for future growth - TradingView
Charles River Laboratories International (CRL) Gains on Strong Results and Resilient Drug Outsourcing Demand - Yahoo Finance
A Look At Charles River Laboratories (CRL) Valuation After 2026 Guidance Cut And Planned Divestitures - Yahoo Finance UK
Dimensional Fund Advisors LP Purchases 120,207 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
A Look Back at Drug Development Inputs & Services Stocks' Q4 Earnings: Charles River Laboratories (NYSE:CRL) Vs The Rest Of The Pack - Finviz
How Investors Are Reacting To Charles River Laboratories (CRL) Cutting 2026 Guidance After Planned Divestitures - Yahoo Finance
GW&K Investment Management LLC Increases Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Why Charles River Laboratories International Inc. stock is upgraded to buy2025 Sector Review & AI Enhanced Trading Alerts - Naître et grandir
Quantbot Technologies LP Invests $1.44 Million in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International (CRL) Faces Biotech R&D Spending Headwinds - Insider Monkey
Picton Mahoney Asset Management Boosts Stock Holdings in Charles River Laboratories International, Inc. $CRL - MarketBeat
LaPlume buys Charles River Labs [CRL] shares worth $4363 - Investing.com India
How Charles River Laboratories International Inc. (CRL) Affects Rotational Strategy Timing - Stock Traders Daily
Risk Hedge: Is Charles River Laboratories International Inc a potential multi baggerTrade Exit Summary & Safe Capital Preservation Plans - baoquankhu1.vn
Charles River Laboratories: Why Wall Street Suddenly Cares About This Quiet Biotech Powerhouse - AD HOC NEWS
Insider Buying: Joseph Laplume Acquires Shares in Charles River Laboratories International Inc (CRL) - GuruFocus
Charles River (NYSE: CRL) CEO receives 16,796-share stock-based award - Stock Titan
Charles River (NYSE: CRL) EVP adds 25 shares in open-market buy - Stock Titan
Charles River Laboratories: Is Wall Street Underpricing This Quiet Biotech Enabler? - AD HOC NEWS
Charles River (CRL) Trims 2026 Outlook After Divestitures and Leadership Changes Is The Strategy Working? - simplywall.st
Charles River Laboratories International, Inc. $CRL Shares Sold by Citigroup Inc. - MarketBeat
Assessing Charles River Laboratories (CRL) Valuation After Recent Mixed Share Price Performance - simplywall.st
Charles River expands footprint at Heriot-Watt University Research Park - Heriot-Watt University
Charles River Laboratories to Present at TD Cowen and Barclays Conferences - Business Wire
Charles River Laboratories (CRL) Stock Analysis: Navigating the Healthcare Research Sector with 10.48% Upside Potential - DirectorsTalk Interviews
Charles River Laboratories Experiences Evaluation Revision Amidst Mixed Market Indicators - Markets Mojo
Could Cash Machine Charles River Laboratories International Stock Be Your Next Buy? - Trefis
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River Laboratories parts ways with its CDMO business - European Pharmaceutical Review
Charles River Laboratories International, Inc. $CRL Stock Holdings Increased by JPMorgan Chase & Co. - MarketBeat
Charles River Laboratories to divest a number of assets to IQVIA and GI Partners - Business Weekly
IQVIA to acquire Charles River drug discovery assets - Yahoo Finance
Charles River to sell CDMO and European discovery assets By Investing.com - Investing.com Australia
Charles River Laboratories Experiences Revision in Its Stock Evaluation Amid Mixed Financial Indicators - Markets Mojo
UBS Group Issues Positive Forecast for Charles River Laboratories International (NYSE:CRL) Stock Price - MarketBeat
Activist investor prompts sale of Charles River CDMO business, U.S. and European sites - The Business Journals
IQVIA Holdings Inc. (NYSE : IQV) entered into a definitive agreement to acquire European Discovery Services Assets from Charles River Laboratories International, Inc. (NYSE - marketscreener.com
Charles River Laboratories (CRL) Announces Strategic Divestitures to Streamline Operations - GuruFocus
UBS Adjusts Price Target on Charles River Laboratories International to $175 From $170, Maintains Neutral Rating - marketscreener.com
Sector Update: Health Care - marketscreener.com
Charles River Labs Breaks The Mold, Announces Bold Divestiture Plans - Benzinga
Charles River announces divestitures, updates guidance - MSN
Charles River to sell CDMO and European discovery assets - Investing.com
Charles River Laboratories stock rises on divestiture plans By Investing.com - Investing.com Australia
IQVIA to acquire drug discovery assets from Charles River Labs - Investing.com
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.17%
0.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):